Difference between revisions of "Cancer drugs"
Jump to navigation
Jump to search
(create) |
|||
| Line 33: | Line 33: | ||
| notes? | | notes? | ||
|- | |- | ||
| | | fulvestrant | ||
| Faslodex | | Faslodex | ||
| 719 Euros/month<ref name=spiegel8_8_11_124/> | | 719 Euros/month<ref name=spiegel8_8_11_124/> | ||
| breast cancer | | breast cancer | ||
| | | selective estrogen receptor down-regulator (SERD) | ||
|- | |- | ||
| | | letrozole | ||
| Femara | | Femara | ||
| 4189 Euros/month<ref name=spiegel8_8_11_124/> | | 4189 Euros/month<ref name=spiegel8_8_11_124/> | ||
| indication | | indication | ||
| | | non-steroidal aromatase inhibitor | ||
|- | |- | ||
| | | imatinib | ||
| Glivec | | Gleevec/Glivec | ||
| 4189 Euros/month<ref name=spiegel8_8_11_124/> | | 4189 Euros/month<ref name=spiegel8_8_11_124/> | ||
| ALL, CML | | ALL, CML | ||
| | | tyrosine kinase inhibitor | ||
|- | |- | ||
| non-proprietary name | | non-proprietary name | ||
| Line 57: | Line 57: | ||
| notes? | | notes? | ||
|- | |- | ||
| | | nilotinib | ||
| Tasigna | | Tasigna | ||
| 5685 Euros/month<ref name=spiegel8_8_11_124/> | | 5685 Euros/month<ref name=spiegel8_8_11_124/> | ||
| CML | | CML | ||
| | | tyrosine kinase inhibitor | ||
|- | |- | ||
| | | lapatinib | ||
| Tyverb | | Tyverb | ||
| 3441 Euros/month<ref name=spiegel8_8_11_124/> | | 3441 Euros/month<ref name=spiegel8_8_11_124/> | ||
| breast cancer | | breast cancer | ||
| | | tyrosine kinase inhibitor / HER2 growth receptor pathway blockade | ||
|} | |} | ||
Revision as of 02:50, 15 August 2011
This article covers cancer drugs from a pathology perspective.
Drugs in a table
| Non-proprietary name | Trade name | Cost | Indication | Notes |
|---|---|---|---|---|
| cetuximab | Erbitux | 5267 Euros/month[1] | stomach cancer, head & neck cancer | notes? |
| trastuzumab | Herceptin | 3345 Euros/month[1] | breast cancer, stomach cancer | notes? |
| non-proprietary name | Iressa | 3496 Euros/month[1] | Lung cancer | notes? |
| panitumumab | Vectibix | 3537 Euros/month[1] | indication | notes? |
| fulvestrant | Faslodex | 719 Euros/month[1] | breast cancer | selective estrogen receptor down-regulator (SERD) |
| letrozole | Femara | 4189 Euros/month[1] | indication | non-steroidal aromatase inhibitor |
| imatinib | Gleevec/Glivec | 4189 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
| non-proprietary name | Sprycel | 7513 Euros/month[1] | ALL, CML | notes? |
| nilotinib | Tasigna | 5685 Euros/month[1] | CML | tyrosine kinase inhibitor |
| lapatinib | Tyverb | 3441 Euros/month[1] | breast cancer | tyrosine kinase inhibitor / HER2 growth receptor pathway blockade |